Issue: March 2017, Posted Date: 3/8/2017
Accelerating Development of Enabled Formulations for Poorly Soluble Drugs
Efficacy issues due to inadequate
gastrointestinal (GI) absorption caused by insufficient aqueous solubility are
encountered in up to 70% of new drugs in development. Often solubility issues
are often only discovered when the drug is first administered in clinical
trials. Quotient Clinical has developed an innovative approach to identify and
overcome solubility challenges, which enables formulations to be designed,
manufactured and clinically evaluated rapidly. Data from the early stages of
the clinical evaluation can be fed back into the process, allowing formulations
to be modified, manufactured and passed straight into the clinic again. This
unique approach means that formulation issues can be detected, corrected and
clinically validated more quickly. Click here to download/view the whitepaper.
This record has been viewed 373 times.